Stock Research: Bristol-Myers Squibb

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Bristol-Myers Squibb

NYQ:BMY US1101221083
42
  • Value
    85
  • Growth
    26
  • Safety
    Safety
    31
  • Combined
    37
  • Sentiment
    57
  • 360° View
    360° View
    42
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases. It operates in oncology, hematology, immunology, and neuroscience. The company operates globally. In the last fiscal year, the company had a market cap of $94,489 million, profits of $36,351 million, revenue of $48,300 million, and 34,100 employees.

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
85 92 92 97
Growth
26 43 7 27
Safety
Safety
31 30 31 35
Sentiment
57 40 68 51
360° View
360° View
42 51 39 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
9 9 10 34
Opinions Change
66 12 48 64
Pro Holdings
n/a 88 87 40
Market Pulse
84 79 78 68
Sentiment
57 40 68 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
85 92 92 97
Growth
26 43 7 27
Safety Safety
31 30 31 35
Combined
37 58 29 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
72 43 37 40
Price vs. Earnings (P/E)
19 83 91 96
Price vs. Book (P/B)
34 23 19 35
Dividend Yield
97 98 98 98
Value
85 92 92 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
26 6 25 11
Profit Growth
61 100 31 47
Capital Growth
32 17 26 48
Stock Returns
38 61 37 73
Growth
26 43 7 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
17 16 24 34
Refinancing
34 27 25 25
Liquidity
83 75 76 66
Safety Safety
31 30 31 35

Similar Stocks

Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: